Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GT Biopharma ( (GTBP) ) has issued an update.
In September 2025, GT Biopharma‘s Series L Preferred Stockholders agreed to waive their redemption rights, as outlined in the Certificate of Designations. This waiver potentially impacts the company’s financial flexibility and stakeholder interests by altering the terms of preferred stock agreements.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma operates in the biopharmaceutical industry, focusing on the development of innovative therapies for cancer treatment.
Average Trading Volume: 214,529
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
Learn more about GTBP stock on TipRanks’ Stock Analysis page.